Market revenue in 2023 | USD 36.9 million |
Market revenue in 2030 | USD 193.1 million |
Growth rate | 26.7% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.12% in 2023. Horizon Databook has segmented the Argentina cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
Argentina is considered as one of the most advanced countries in terms of regulatory legislation in Latin America. It is a lucrative market for CDMO due to the increasing need for highly optimized manufacturing processes, rising prevalence of diseases, and growing vaccine development & production.
Moreover, biopharmaceutical companies are taking different strategic initiatives to strengthen their market position, such as M&A, partnership, and investment, which further contribute to market. For instance, in February 2024, mAbxience and Biosidus signed a CDMO agreement for manufacturing Agalsidase Beta, a biosimilar for Fabry disease treatment, marking a strategic breakthrough for both companies in the biopharmaceutical industry.
In addition, the country has aligned regulations of clinical research with international standards & requirements, which permits laboratories to conduct clinical trials on behalf of big pharmaceutical companies in developed countries.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Argentina cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account